China News Service, November 20. According to Singapore’s “Lianhe Zaobao” report, on the 19th local time, European Commission President Von der Lein stated that the EU may grant conditional sales licenses for the two new crown vaccines in late December. The United States "synchronized" began to distribute vaccines.
The President of the European Commission von der Lein.
According to reports, von der Lein said that the European Medicines Agency may, as early as late December, deal with the new crown vaccine jointly developed by Pfizer and its German partner BioNTech, and the US pharmaceutical company Modena’s Conditional license is granted for the new crown vaccine.
Von Delane said that the European Medicines Agency and the US Food and Drug Administration maintain daily communication in order to "synchronize" the evaluation of the vaccine.
It was previously reported that Pfizer would apply for emergency use authorization in the United States on the 20th.
First-line medical staff in the United States are expected to receive the first batch of new crown vaccines at the end of December 2020 or early January 2021.
According to Reuters, citing unnamed EU officials, the EU may spend more than US$10 billion to purchase hundreds of millions of doses of vaccines developed by Pfizer and German vaccine research and development company CureVac.
According to the report, the European Union agreed to purchase Pfizer's vaccine candidate at a price of about $18.3 per dose, which is lower than the United States.
At present, as the weather begins to get colder, a new wave of severe epidemics has appeared in many European countries, and governments have implemented new blockade measures.
EU leaders held a video conference on the evening of the 19th to discuss the fight against the new crown epidemic, emphasizing the strengthening of coordination in rapid testing and vaccination.